The effects of celecoxib on inflammation and synovial microcirculation in murine antigen-induced arthritis

Clinical and Experimental Rheumatology

Volumn 23, Issue 1, 2005, Pages 63-70

  Gebhard, Harry H ^a   Zysk, Stefan P ^a   Schmitt Sody, Markus ^a   Jansson, Volkmar ^a   Messmer, Konrad ^a   Veihelmann, Andreas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Adhesion molecules; Antigen induced arthritis; Celecoxib; Cyclooxygenase 2; Intravital microscopy

Indexed keywords

ANTIGEN; CELECOXIB; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; ENDOTHELIUM; ENZYME INHIBITION; FEMALE; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE COUNT; MICROCIRCULATION; MICROSURGERY; MICROVASCULATURE; MOUSE; MOUSE STRAIN; NONHUMAN; PATELLA TENDON; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNOVIUM;

ANIMALS; ANTIGENS; ARTHRITIS; CELL ADHESION MOLECULES; CELL COMMUNICATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; INFLAMMATION; MICE; MICE, INBRED BALB C; MICROCIRCULATION; MODELS, ANIMAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; SYNOVIAL MEMBRANE;

EID: 15844377442     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
2. FLETCHER BS, KUJUBU DA, PERRIN DM, HERRSCHMANN HR: Structure of the mitogen-inducible TIS 10 gene and demonstration that the TIS 10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992; 267: 4338-44.
3. McKENNA F, ARGUELLES L, BURKE T, LEFKOWITH J, GEIS GS: Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 2002; 20: 35-43.
4. SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. Jama 1999; 282: 1921-8.
5. MARICIC N, EHRLICH K, GRETZER B, SCHULIGOI R, RESPONDEK M, PESKAR BM: Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol 1999; 128: 1659-66.
6. CUZZOCREA S, MAZZON E, SERRAINO I et al.: Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol 2001; 431: 91-102.
7. KROMBACH F: Molekulare Mechanismen der Leukozyten-Endothelzell Interaktion. Intensivmed 1996; 33: 375-85.
8. BISHOP-BAILEY D, BURKE-GAFFNEY A, HELLEWELL PG, PEPPER JR, MITCHELL JA: Cyclo-oxygenase-2 regulates inducible ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 249: 44-7.
9. SANO H, HLA T, MAIER JA et al.: In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992; 89: 97-108.
10. VEIHELMANN A, HARRIS AG, KROMBACH F, SCHUTZE E, REFIOR HJ, MESSMER K: In vivo assessment of synovial microcirculation and leukocyte-endothelial cell interaction in mouse antigen-induced arthritis. Microcirculation 1999; 6: 281-90.
11. BRACKERTZ D, MITCHELL GF, MACKAY IR: Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 1977; 20: 841-50.
12. VEIHELMANN A, SZCZESNY G, NOLTE D, KROMBACH F, REFIOR HJ, MESSMER K: A novel model for the study of synovial microcirculation in the mouse knee joint in vivo. Res Exp Med (Berl) 1998; 198: 43-54.
13. HARRIS AG, HECHT R, PEER F, NOLTE D, MESSMER K: An improved intravital microscopy system. Int J Microcirc Clin Exp 1997; 17: 322-7.
14. ZEINTL H, SACK FU, INTAGLIETTA M, MESSMER K: Computer assisted leukocyte adhesion measurement in intravital microscopy. Int J Microcirc Clin Exp 1989; 8: 293-302.
15. MUSCARA MN, VERGNOLLE N, LOVREN F et al.: Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000; 129: 1423-30.
16. HARRIS A, SCHROPP A, MESSMER K: Effects of oxaceprol on the microcirculation in ischemia/reperfusion injury. Eur J Med Res 1998; 3: 182-8.
17. GEARING AJ, NEWMAN W: Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.
18. COMINACINI L, PASINI A, GARBIN U et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15: 891-5.
19. NEEDLEMAN P, ISAKSON PC: The discovery and function of COX-2. J Rheumatol 1997; 24 Suppl 49: 6-8.
20. MIGITA K, YAMASAKI S, IDA H et al.: The role of peroxynitrite in cyclooxygenase-2 expression of rheumatoid synovium. Clin Exp Rheumatol 2002; 20: 59-62
21. NAKAMURA Y, KOZUKA M, NANIWA K et al.: Arachidonic acid cascade inhibitors modulate phorbol ester-induced oxidative stress in female ICR mouse skin: differential roles of 5-lipoxygenase and cyclooxygenase-2 in leukocyte infiltration and activation. Free Radic Biol Med 2003; 35: 997-1007.
22. HOCHBERG MC: New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum 2002; 32: 4-14.
23. WILGUS TA, ROSS MS, PARRETT ML, OBERYSZYN TM: Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat 2000; 62: 367-84.
24. ANDERSON GD, HAUSER SD, McGARITY KL, BREMER ME, ISAKSON PC, GREGORY SA: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-9.
25. OCHI T, OHKUBO Y, MUTOH S: Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice. Biochem Pharmacol 2003; 66: 1055-60.